Clinical trials

  • TRAMETINIB for Metastatic melanoma | Non-small cell lung cancer
  • SACITUZUMAB TIRUMOTECAN for Gastroesophageal adenocarcinoma | Gastric adenocarcinoma | Gastroesophageal junction adenocarcinoma | Esophageal adenocarcinoma
  • VANGLUSAGENE ENSIPARVOVEC for Late-onset Pompe disease|Pompe disease (Glycogen storage disease type II)
  • Synthetic double-stranded siRNA oligonucleotide directed against apolipoprotein C-III mRNA and covalently linked to a GalNAc ligand (three N-acetylgalactosamine residues) for Severe hypertriglyceridemia
  • ticagrelor for Severe Symptomatic Aortic Stenosis
  • BNT116 for Advanced non-small cell lung cancer
  • Obinutuzumab for Follicular lymphoma (early stage)
  • Dabrafenib mesylate for BRAF V600-mutant cancers
  • Atezolizumab for Locally advanced or metastatic solid tumor|Ovarian cancer|Clear cell renal cell carcinoma
  • DATOPOTAMAB DERUXTECAN for Triple-negative breast cancer (locally recurrent inoperable or metastatic)
  • metformin for Polycystic ovary syndrome
  • MR0005, GR0015 for Alpha-1 antitrypsin deficiency (AATD)-associated lung disease|Alpha-1 antitrypsin deficiency (AATD)-associated liver disease